AI Agents in Action: How Digital Colleagues Are Changing the Way We Work - On Record PR
Innovation in Compliance: Mastering Communication: Insights from Dr. Dennis Cummins on Speaking and Selling without Selling
Fox on Podcasting: PodPage and Beyond: Elevating Listener Experience with Dave Jackson
Innovation in Compliance: The Future of Compliance Training: AI, Adaptive, Learning, and Cultural
Can Food Really Be Medicine? Transforming Health Care One Bite at a Time – Diagnosing Health Care Video Podcast
The Rise of OTAs in Defense Contracting: Opportunities, Risks, and What Contractors Need to Know
Future-Ready – Equipping MBD Teams to Navigate and Leverage Emerging Technologies
AI in eDiscovery Today: An Open Conversation
Innovation in Compliance: Allison Lagosh on Proactive Compliance Planning for Regulatory Changes
Innovation in Compliance: Maximizing LinkedIn for Personal and Professional Branding with Carol Kaemmerer
Innovation in Compliance: The Critical Importance of Mobile Application Security: Insights from Subho Halder
Meet Phil Leslie, Cornerstone Research's New Chief Technology and Innovation Officer
Innovation in Compliance: Integrating AI in Compliance and Risk Management with Jana Brost
The Future of Supply Chains: Chris Andrassy on Using AI to Predict & Prevent Disruptions
Innovation in Compliance: Break the Five Lies - A Conversation with John Kormanik
Compliance Tip of the Day: Using Supply Chain to Innovate in Compliance
Innovation in Compliance: Innovative Approaches to Compliance and Training with Catherine Choe
Innovation in Compliance: Exploring the Fractional COO Model with La Tonya Roberts
Innovation in Compliance: Design-Centric Compliance Training with Karen Oddo
Innovation in Compliance: Strategic Compliance in Regulated Industries with Kerri Reuter
The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug exclusion, a once narrow exception that permitted manufacturers of rare disease drugs and biologics to be...more
Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical...more
On August 18, 2017, President Trump signed into law the FDA Reauthorization Act (FDARA). FDARA reauthorizes user fees paid to FDA to support regulatory review of innovator drugs and biologics, medical devices, generic drugs,...more